Report
Eric Le Berrigaud

Pharmaceuticals: Feedback ESMO 2019 – Part II – Other Cancers

Pharmaceuticals
Feedback ESMO 2019 – Part II – Other Cancers

GSK vs AZ: the patient wins new SoC in 1L ovarian cancer
CDK4-6 inhibitors confirm their status as SoC in HR+/HER2- BC
Suggested changes to the guidelines in RCC
Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Eric Le Berrigaud

ResearchPool Subscriptions

Get the most out of your insights

Get in touch